AssetMark’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.96K Sell
265
-111
-30% -$2.24K ﹤0.01% 2775
2026
Q2
$7.52K Buy
376
+111
+42% +$1.96K ﹤0.01% 2559
2026
Q1
$4.31K Hold
265
– – ﹤0.01% 2622
2025
Q4
$4.45K Hold
265
– – ﹤0.01% 2504
2025
Q3
$4.11K Hold
265
– – ﹤0.01% 2410
2025
Q2
$3.4K Buy
+265
New +$3.27K ﹤0.01% 2256

Other funds holding HQL

AssetMark's HQL Position: Q3 2026 in Review

AssetMark reduced its abrdn Life Sciences Investors (HQL) stake by 30% in Q3 2026, selling an estimated $2.24K and leaving 265 shares worth $4.96K. The position accounts for ﹤0.01% of the portfolio, ranked #2775.

AssetMark first reported a position in HQL in Q2 2025 and has held it in 6 quarters since. The position peaked at $7.52K in Q2 2026. 74 funds tracked by Wall St. Rank hold HQL as of Q3 2026.

  • AssetMark held 265 shares of abrdn Life Sciences Investors worth $4.96K as of Q3 2026.
  • AssetMark sold 111 abrdn Life Sciences Investors shares in Q3 2026, an estimated $2.24K.
  • abrdn Life Sciences Investors made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2775 holding.
  • AssetMark first reported a position in abrdn Life Sciences Investors in Q2 2025 and has held it in 6 quarters since.
  • AssetMark's abrdn Life Sciences Investors position peaked at $7.52K in Q2 2026.
  • 74 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.